Status:
COMPLETED
Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Neuropathic Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will measure the impact of treatment with pregabalin in adult men and women who have a diagnosis of peripheral neuropathic pain (pain caused by a primary lesion of the peripheral nervous sy...
Eligibility Criteria
Inclusion
- Subjects presenting a diagnosis of peripheral neuropathic pain, defined as pain caused by a lesion of the peripheral nervous system manifesting with sensory symptoms and signs, for at least 6 months at screening.
- At baseline, subjects must have completed at least 4 daily pain diaries and must have a mean weekly pain score equal or greater than 4.
Exclusion
- Presence of any of the following diagnoses: Cervical or lumbo-sacral radiculopathy; Operated or non-operated chronic low back pain Carpal tunnel syndrome or any other entrapment-related neuropathic pain (defined as pain associated with focal nerve lesion produced by constriction or mechanical distortion of the nerve, within a fibrous or fibro-osseous tunnel, or by a fibrous band) ; Complex regional pain syndrome (type 1 and 2); Fibromyalgia.
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
158 Patients enrolled
Trial Details
Trial ID
NCT00219544
Start Date
November 1 2005
End Date
February 1 2008
Last Update
January 22 2021
Active Locations (30)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Calgary, Alberta, Canada, T2N 4N1
2
Pfizer Investigational Site
Calgary, Alberta, Canada, T2S 3C3
3
Pfizer Investigational Site
Calgary, Alberta, Canada, T3B 0M3
4
Pfizer Investigational Site
Edmonton, Alberta, Canada, T5J 3N4